Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Abstract Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2021-04, Vol.72 (7), p.1247-1250
Hauptverfasser: Titanji, Boghuma K, Farley, Monica M, Mehta, Ashish, Connor-Schuler, Randi, Moanna, Abeer, Cribbs, Sushma K, O’Shea, Jesse, DeSilva, Kathryn, Chan, Bonnie, Edwards, Alex, Gavegnano, Christina, Schinazi, Raymond F, Marconi, Vincent C
Format: Artikel
Sprache:eng
Schlagworte:
Antiviral Agents - therapeutic use
Azetidines
Brief Reports
COVID-19 - drug therapy
Humans
Purines
Pyrazoles
Retrospective Studies
SARS-CoV-2
Sulfonamides
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciaa879